Physician profile
Bryan Lebean
NPI 1821052754
$53,325.14
in general payments reported to CMS, 2019-2025
56 companies · $2,858 in 2025
The $2,858 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,392 · 2020: $1,778 · 2021: $11K · 2022: $20K · 2023: $14K · 2024: $2,512 · 2025: $2,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $8,154 · Education: $188 · Consulting Fee: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,978.50 |
| Food and Beverage | $8,154.27 |
| Education | $187.89 |
| Consulting Fee | $149.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22,590.43 | 2021-2025 | |
| Apria Healthcare LLC | $8,336.00 | 2021 | |
| Idorsia Pharmaceuticals US INC | $6,829.63 | 2022-2024 | Quviviq |
| Novo Nordisk INC | $2,471.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,540.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Harmony Biosciences LLC | $1,268.45 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $1,025.62 | 2019-2025 | Xywav |
| Lilly USA, LLC | $1,022.52 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $878.04 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $586.34 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $562.94 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.63 | 2019-2024 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $451.99 | 2019-2025 | Leqvio |
| Coloplast Corp | $440.99 | 2023-2025 | Titan |
| Mylan Specialty L.P. | $439.50 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Lebean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.